Last reviewed · How we verify
Relugolix and Enzalutamide (relugolix-and-enzalutamide)
Relugolix and Enzalutamide work by inhibiting androgen receptors and reducing luteinizing hormone, lowering testosterone levels to treat prostate cancer.
At a glance
| Generic name | relugolix-and-enzalutamide |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Mechanism of action
Relugolix blocks the release of luteinizing hormone, which in turn reduces testosterone production. Enzalutamide directly binds to androgen receptors on cancer cells, preventing them from growing.
Approved indications
Common side effects
Key clinical trials
- Relugolix + Enzalutamide Study in High-Risk Prostate Cancer (PHASE1)
- Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (PHASE2)
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (PHASE2)
- Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) (PHASE2)
- First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (PHASE2)
- Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial (PHASE2)
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Relugolix and Enzalutamide CI brief — competitive landscape report
- Relugolix and Enzalutamide updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI